Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Saumya S Gurbani"'
Autor:
Karthik K. Ramesh, Vicki Huang, Jeffrey Rosenthal, Eric A. Mellon, Mohammed Goryawala, Peter B. Barker, Saumya S. Gurbani, Anuradha G. Trivedi, Alexander S. Giuffrida, Eduard Schreibmann, Hui Han, Macarena de le Fuente, Erin M. Dunbar, Matthias Holdhoff, Lawrence R. Kleinberg, Hui-Kuo G. Shu, Hyunsuk Shim, Brent D. Weinberg
Publikováno v:
Tomography, Vol 9, Iss 1, Pp 362-374 (2023)
Glioblastoma (GBM) is a fatal disease, with poor prognosis exacerbated by difficulty in assessing tumor extent with imaging. Spectroscopic MRI (sMRI) is a non-contrast imaging technique measuring endogenous metabolite levels of the brain that can ser
Externí odkaz:
https://doaj.org/article/7e1bf384b7a148daa2140d6801c84cdc
Autor:
Karen Xu, Karthik Ramesh, Vicki Huang, Saumya S. Gurbani, James Scott Cordova, Eduard Schreibmann, Brent D. Weinberg, Soma Sengupta, Alfredo D. Voloschin, Matthias Holdhoff, Peter B. Barker, Lawrence R. Kleinberg, Jeffrey J. Olson, Hui-Kuo G. Shu, Hyunsuk Shim
Publikováno v:
Tomography, Vol 8, Iss 2, Pp 688-700 (2022)
Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical tria
Externí odkaz:
https://doaj.org/article/c5d64c1e66924dba9ace3ae3ee5433e3
Autor:
Hui-Kuo Shu, Alfredo Voloschin, Soma Sengupta, Vicki Huang, Brent D. Weinberg, Jeffrey J. Olson, Peter B. Barker, Saumya S. Gurbani, Karen M. Xu, Karthik Ramesh, Matthias Holdhoff, Lawrence Kleinberg, Hyunsuk Shim, Eduard Schreibmann, J. Scott Cordova
Publikováno v:
Tomography; Volume 8; Issue 2; Pages: 688-700
PurposeGlioblastoma (GBM) is highly aggressive with poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and potential to enhance chemoradiation. The purpose of this clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d2b4f1f4958a52150db2a4f920514f
https://pubmed.ncbi.nlm.nih.gov/35314634
https://pubmed.ncbi.nlm.nih.gov/35314634
Autor:
Karthik Ramesh, Eric A Mellon, Saumya S Gurbani, Brent D Weinberg, Eduard Schreibmann, Sulaiman A Sheriff, Mohammed Goryawala, Macarena de le Fuente, Bree R Eaton, Jim Zhong, Alfredo D Voloschin, Soma Sengupta, Erin M Dunbar, Matthias Holdhoff, Peter B Barker, Andrew A Maudsley, Lawrence R Kleinberg, Hyunsuk Shim, Hui-Kuo G Shu
Publikováno v:
Neuro-Oncology Advances. 4
Background Glioblastomas (GBMs) are aggressive brain tumors despite radiation therapy (RT) to 60 Gy and temozolomide (TMZ). Spectroscopic magnetic resonance imaging (sMRI), which measures levels of specific brain metabolites, can delineate regions at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b725818e9bbb2a7072a0ca224479624
https://doi.org/10.1093/noajnl/vdac006
https://doi.org/10.1093/noajnl/vdac006
Autor:
Saumya S. Gurbani, Brent D. Weinberg, David M Brandman, Christopher Reeves, Nicholas M. Boulis
Publikováno v:
Journal of neuroimaging : official journal of the American Society of NeuroimagingREFERENCES. 32(1)
Background and purpose Percutaneous trigeminal tractotomy is an ablative procedure that can be used to treat trigeminal neuralgia in patients who have failed prior pharmacologic and surgical treatments. Using perioperative computed tomography (CT) gu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b98a96476e8801940cc3696a7843dbf8
https://pubmed.ncbi.nlm.nih.gov/34468049
https://pubmed.ncbi.nlm.nih.gov/34468049
Autor:
Karthik Ramesh, Zhongxing Liang, J. Scott Cordova, Saumya S. Gurbani, Robert H. Press, Brent D. Weinberg, José E. Velázquez Vega, Eric Salgado, Eduard Schreibmann, Jeffrey J. Olson, Hui-Kuo Shu, Alfredo Voloschin, Younghyoun Yoon, Hyunsuk Shim
Publikováno v:
Tomography
Tomography; Volume 5; Issue 1; Pages: 53-60
Volume 5
Issue 1
Pages 53-60
Tomography; Volume 5; Issue 1; Pages: 53-60
Volume 5
Issue 1
Pages 53-60
Histone deacetylases regulate a wide variety of cellular functions and have been implicated in redifferentiation of various tumors. Histone deacetylase inhibitors (HDACi) are potential pharmacologic agents to improve outcomes for patients with glioma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86200f57f48444ae85c85129e577ff92
https://doi.org/10.18383/j.tom.2018.00031
https://doi.org/10.18383/j.tom.2018.00031
Autor:
Jim Zhong, Jeffrey J. Olson, Hyunsuk Shim, Saumya S. Gurbani, Eduard Schreibmann, Hui-Kuo Shu, Hui Han, Karthik Ramesh, Vicki Huang, Alexander Giuffrida, Brent D. Weinberg, J. Scott Cordova
Publikováno v:
J Neurooncol
PURPOSE. MRI is the standard imaging modality used for diagnosis, treatment planning, and post-treatment management of gliomas. Contrast-enhanced T1-weighted (CE-T1w) MRI is used to plan biopsy and radiation for grade IV gliomas but is less effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b46ff9160336ceb25e01ed48f2f1fb9
https://europepmc.org/articles/PMC8237861/
https://europepmc.org/articles/PMC8237861/
Autor:
Karthik Ramesh, Hui-Kuo Shu, Alfredo Voloschin, Lawrence Kleinberg, Vicki Huang, Brent D. Weinberg, Soma Sengupta, Eduard Schreibmann, Saumya S. Gurbani, Peter B. Barker, Karen M. Xu, Jeffrey J. Olson, Matthias Holdhoff, Hyunsuk Shim
Publikováno v:
Neuro-Oncology Advances. 3:iv9-iv10
PURPOSE Glioblastomas (GBMs) are highly aggressive brain tumors with poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and potential to enhance chemoradiation. This clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abffb5cefa3fd1ead67e6fcd77aa71b3
https://doi.org/10.1093/noajnl/vdab112.035
https://doi.org/10.1093/noajnl/vdab112.035
Publikováno v:
Journal of Medical Systems
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60dcca57d64f6b1eb6ceb881dcb21db2
Autor:
Peter B. Barker, Karen M. Xu, Soma Sengupta, Hyunsuk Shim, Karthik Ramesh, Vicki Huang, Alfredo Voloschin, Matthias Holdhoff, Brent D. Weinberg, Lawrence Kleinberg, Hui-Kuo Shu, Eduard Schreibmann, Jeffrey J. Olson, Saumya S. Gurbani
Publikováno v:
Neuro Oncol
INTRODUCTION Glioblastoma (GBM) is highly aggressive with poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability that has anti-GBM activity and may enhance effects of chemoradiation. Our institution cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a78c64bc2b41ec608ccc97dca53891e
https://europepmc.org/articles/PMC7650343/
https://europepmc.org/articles/PMC7650343/